Odyssey Health, Inc. 10-Q

Item 5. Other Information During the quarter ended April 30, 2026, no director or officer adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. Item 6. Exhibits The following exhibits are filed herewith and this list constitutes the exhibit index. Exhibit Number Exhibit Description 10.1 Master Technology and Sub-License Agreement between Odyssey Health, Inc. and NeuRX Health, Inc (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on October 17, 2025). 10.2 Amendment No. 1, dated April 21, 2026, to the Master Technology and Sub-License Agreement dated October 14, 2025 (incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on April 24, 2026). 10.3 NeuRX Health, Inc. Revocation Letter dated May 6, 2026 (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 11, 2026) 10.4 Form of Amendment No. 12 dated January 30, 2026, to Convertible Promissory Note with Directors and Officers, dated December 21, 2021 and December 22, 2021 (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on February 3, 2026) 10.5 Amendment No. 11 dated January 30, 2026 to Convertible Promissory Note with LGH Investments, LLC dated April 5, 2021 (incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on February 3, 2025). 10.6 Amendment No. 5 dated January 30, 2026, to the Promissory Note with accredited investor Jonathan Lutz, dated February 13, 2024 (incorporated by reference to Exhibit 10.3 to Form 8-K filed with the SEC on February 3, 2025) 10.7 Amendment No. 2 dated February 2, 2026 and effective January 30, 2026, to the Promissory Note with accredited investor Peter J. D’Arruda, dated August 14, 2024 (incorporated by reference to Exhibit 10.4 to Form 8-K filed with the SEC on February 3, 2026) 10.8 Amendment No. 12 dated May 18, 2026 to Convertible Promissory Note with LGH Investments, LLC dated April 5, 2021 (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 26, 2026). 10.9 Amendment No. 6 dated October 9, 2025 to Promissory Note issued December 13, 2022 with Mast Hill Fund, L.P (incorporated by reference to Exhibit 10. 1 to Form 8-K filed with the SEC on October 10, 2025) 10.10 Amendment No. 7 dated June 9, 2026 to Promissory Note issued December 13, 2022 with Mast Hill Fund, L.P. ** 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 32.1 Certification of Chief Executive Officer pursuant to Section 1350 32.2 Certification of Chief Financial Officer pursuant to Section 1350 101.INS Inline XBRL Instances Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101). ** Filed herewith 26 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, as of June 12, 2026. ODYSSEY HEALTH, INC. By: /s/ Joseph Michael Redmond Joseph Michael Redmond Chief Executive Officer, President and Director (Principal Executive Officer) By: /s/ Christine M. Farrell Christine M. Farrell Chief Financial Officer (Principal Financial and Accounting Officer) 27